Research
-
How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma
Innovations that extend life can generate option value and cost of experiencing future technologies. Schaeffer postdoc Meng Li developed generalizable approaches to estimating option value in cost-effectiveness analysis.
Categorized in -
Material–Psychosocial–Behavioral Aspects of Financial Hardship: A Conceptual Model for Cancer Prevention
RCMAR Scientist Reginald Tucker-Seeley presents a model to consistently measure financial hardship to better inform cancer prevention research identify connections between socioeconomic circumstances and cancer risk-related behaviors and cancer screening among older adults.
-
Allocating Outreach Resources for Disease Control in a Dynamic Population with Information Spread
Infected individuals must be aware of disease symptoms to seek care, so outreach and education programs are critical to disease control.
Categorized in -
Do Health Insurance and Hospital Market Concentration Influence Hospital Patients’ Experience of Care?
The findings from this study add to the evidence on the harms of hospital consolidation but suggest that insurer consolidation may improve patient experience.
Categorized in -
Medicare Physician Payment Reform After Two Years: Examining MACRA Implementation and the Road Ahead
Matthew Fiedler spoke at the Senate Finance Committee on May 8 about the implementation of the Medicare physician payment provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
Categorized in -
Digital Waste? Unintended Consequences of Health Information Technology
Abstract We exploit a large-scale natural experiment – the rollout of a nationwide electronic prescribing system in Finland – to study how digitization of prescriptions affects pharmaceutical use and health outcomes. We use comprehensive administrative data from patients treated with benzodiazepines, which are globally popular, effective but addictive psychotropic medications. We find no impact on […]
Categorized in -
State and Federal Policy Solutions to Rising Prescription Drug Prices in the U.S.
States are addressing drug pricing issues through one of two domains. First, states are targeting drug pricing directly for both branded and generic products. Second, states are exploring topics in drug price transparency. Padula outlines state and federal policy options targeted prescription drugs that are currently being pursued.
Categorized in -
Racial and Educational Disparities in Dementia and Dementia-Free Life Expectancy
We estimate life expectancy with and without dementia for Americans 65 years and older by education and race to examine how these stratification systems combine to shape disparities in later-life cognitive health.
Categorized in -
Geographic Variation in the Delivery of High-Value Inpatient Care
Hospitals in Miami produced 13 percent fewer high-quality hospital stays than the U.S. average, while hospitals in Everett, Washington, a city 25 miles north of Seattle, perform over 20 percent better than average on value.
Categorized in -
Economic Dimensions of Personalized and Precision Medicine
The book explores recent empirical applications of personalized and precision medicine, as well as the intersection of the scientific, clinical, and economic factors affecting the development of PPM.